Science- and Risk-Based Stability Strategies to Support Product Lifecycle Changes.

ICH Q12 asserts that science- and risk-based approaches are applicable to stability studies supporting Chemistry, Manufacturing and Controls (CMC) post-approval changes (PAC) to enable more timely implementation; however, no guidance or specific examples are provided to demonstrate how prior knowledge of the product can inform the risk assessment for the proposed change(s). Ten diverse case studies are presented in this manuscript to demonstrate how science- and risk-based stability strategies were used to support drug substance and product CMC PAC and lifecycle management activities. The accumulated stability knowledge held by original manufacturers of marketed products is substantial, and different elements of this knowledge base were used to assess the risks and impact of the proposed changes for confident change management. This paper provides ways to leverage science- and risk-based stability strategies as part of the post-approval change-management risk-mitigation strategy, which may enable a reduced stability data commitment and/or a reduced reporting category for change implementation.

Considerations for Updates to ICH Q1 and Q5C Stability Guidelines: Embracing Current Technology and Risk Assessment Strategies.

In consideration of the recent ICH Quality Discussion Group (QDG) recommended revision to the ICH series of stability guidelines, the IQ Consortium (International Consortium for Innovation and Quality in Pharmaceutical Development) Science- and Risk-based Stability Working Group conducted a comprehensive review of ICH Q1A, Q1B, Q1C, Q1D, Q1E, and Q5C to identify areas where the guidelines could be clarified, updated, and amended to reflect the potential knowledge gained from current risk-based predictive stability tools and to consider other science- and risk-based stability strategies in accordance with ICH Q8-12. The recommendations propose a holistic approach to stability understanding, utilizing historical data, prior knowledge, modeling, and a risk assessment process to expand the concept of what could be included (or would be acceptable) in the core stability data package, including type and amount of stability evidence, assignment of retest period and shelf-life for a new product, and assessment of the impact of post-approval changes.

Artifactual degradation of secondary amine-containing drugs during accelerated stability testing when saturated sodium nitrite solutions are used for humidity control.

Accelerated stability studies of pharmaceutical products are commonly conducted at various combinations of temperature and relative humidity (RH). The RH of the sample environment can be controlled to set points using humidity-controlled stability chambers or via storage of the sample in a closed container in the presence of a saturated aqueous salt solution. Herein we report an unexpected N-nitrosation reaction that occurs upon storage of carvedilol- or propranolol-excipient blends in a stability chamber in the presence of saturated sodium nitrite (NaNO2) solution to control relative humidity (∼60% RH). In both cases, the major products were identified as the corresponding N-nitroso derivatives of the secondary amine drugs based on mass spectrometry, UV-vis and retention time. These degradation products were not observed upon storage of the samples at the same temperature and humidity but in the presence of saturated potassium iodide (KI) solution (∼60% RH) for humidity control. The levels of the N-nitrosamine derivatives varied with the pH of various NaNO2 batches. The presence of volatile NOx species in the headspace of a container containing saturated NaNO2 solution was confirmed via the Griess assay. The process for formation of the N-nitrosamine derivatives is proposed to involve volatilization of nitric oxide (NO) from aqueous nitrite solution into the headspace of the container followed by diffusion into the solid drug-excipient blend and subsequent reaction of NOx with the secondary amine.

Development of an in vivo-relevant drug product performance method for an amorphous solid dispersion.

The purpose of this work was to develop a meaningful in vitro dissolution method for evacetrapib spray-dried dispersion (SDD) tablets that is discriminating for crystalline drug substance (DS) content. Justification of the method conditions included evaluation of dissolution media, rotation speed, surfactant selection and level of surfactant to achieve sink conditions. Discrimination was illustrated by testing SDD tablets spiked with 10%, 20%, and 30% crystalline DS. The results demonstrated a 13%, 22% and 32% drop in the dissolution end point, respectively, as compared to unspiked SDD tablets. Additionally, tablets containing crystalline DS and tablets containing SDD were tested in a relative bioavailability (RBA) study. Utilizing the proposed dissolution method, the dissolution end point of SDD tablets was determined to be approximately 4 fold higher than that of the tablets containing crystalline DS. These results compare favourably to the in vivo RBA study results where SDD tablets had a 4.6 fold increase in exposure compared to tablets containing crystalline DS.

Confining standing waves in optical corrals.

Near-field scanning optical microscopy images of solid wall, circular, and elliptical microscale corrals show standing wave patterns confined inside the structures with a wavelength close to that of the incident light. The patterns inside the corrals can be tuned by changing the size and material of the walls, the wavelength of incident light, and polarization direction for elliptical corrals. Finite-difference time-domain calculations of the corral structures agree with the experimental observations and reveal that the electric and magnetic field intensities are out of phase inside the corral. A theoretical modal analysis indicates that the fields inside the corrals can be attributed to p- and s-polarized waveguide modes, and that the superposition of the propagating and evanescent modes can explain the phase differences between the fields. These experimental and theoretical results demonstrate that electromagnetic fields on a dielectric surface can be controlled in a predictable manner.

Optical properties of surface-patterned nanostructures.

This concepts article describes our developments in nanopatterning related to photonics. We have a nanopatterning toolkit that can generate functional, nanostructured surfaces at nm-length scales and over cm(2)-areas in a single (or small number of) step(s). This paper will focus on three examples of surface-patterned nanostructures and their optical properties: (i) one-dimensional arrays of metallic nanoparticles; (ii) arrays of small-diameter ZnO nanowires; (iii) mesoscale structures of CdSe/ZnS nanocrystals. The potential for advances in nanopatterning to contribute to a broad range of light-based applications will be discussed.

Synthesis and characterization of phosphorescent cyclometalated platinum complexes.

The synthesis, electrochemistry, and photophysics of a series of square planar Pt(II) complexes are reported. The complexes have the general structure C(wedge)NPt(O(wedge)O),where C(wedge)N is a monoanionic cyclometalating ligand (e.g., 2-phenylpyridyl, 2-(2'-thienyl)pyridyl, 2-(4,6-difluorophenyl)pyridyl, etc.) and O(wedge)O is a beta-diketonato ligand. Reaction of K(2)PtCl(4) with a HC(wedge)N ligand precursor forms the chloride-bridged dimer, C(wedge)NPt(mu-Cl)(2)PtC(wedge)N, which is cleaved with beta-diketones such as acetyl acetone (acacH) and dipivaloylmethane (dpmH) to give the corresponding monomeric C(wedge)NPt(O(wedge)O) complex. The thpyPt(dpm) (thpy = 2-(2'-thienyl)pyridyl) complex has been characterized using X-ray crystallography. The bond lengths and angles for this complex are similar to those of related cyclometalated Pt complexes. There are two independent molecular dimers in the asymmetric unit, with intermolecular spacings of 3.45 and 3.56 A, consistent with moderate pi-pi interactions and no evident Pt-Pt interactions. Most of the C(wedge)NPt(O(wedge)O) complexes display a single reversible reduction wave between -1.9 and -2.6 V (vs Cp(2)Fe/Cp(2)Fe(+)), assigned to largely C(wedge)N ligand based reduction, and an irreversible oxidation, assigned to predominantly Pt based oxidation. DFT calculations were carried out on both the ground (singlet) and excited (triplet) states of these complexes. The HOMO levels are a mixture of Pt and ligand orbitals, while the LUMO is predominantly C(wedge)N ligand based. The emission characteristics of these complexes are governed by the nature of the organometallic cyclometalating ligand allowing the emission to be tuned throughout the visible spectrum. Twenty-three different C(wedge)N ligands have been examined, which gave emission lambda(max) values ranging from 456 to 600 nm. Well-resolved vibronic fine structure is observed in all of the emission spectra (room temperature and 77 K). Strong spin-orbit coupling of the platinum atom allows for the formally forbidden mixing of the (1)MLCT with the (3)MCLT and (3)pi-pi states. This mixing leads to high emission quantum efficiencies (0.02-0.25) and lifetimes on the order of microseconds for the platinum complexes.